Tuesday - January 20, 2015 Countdown begins for an unparalleled flight Helping to turn a dream into reality, innovative products from Bayer MaterialScience support Solar Impulse as the project team hope to make the first circumnavigation of the earth without fuel more
Tuesday - December 09, 2014 United against human river blindness Bayer and the Drugs for Neglected Diseases initiative have agreed to tackle the world’s second leading infectious cause of blindness, river blindness, widely spread in sub-Saharan Africa more
Tuesday - December 02, 2014 Perspective on innovation 2014 Bayer steps up its focus on research and development as budget reaches EUR 3.2 billion in 2014, with more than 50 projects in the pharmaceuticals pipeline and nearly 500 patents applied for in the life sciences in 2013 more
Monday - November 17, 2014 Historic donation helps protect and save lives Bayer donations for Ebola patients now surpass €3.7 million as more antibiotics and protective clothing are sent to help people in Liberia and Sierra Leone more
Thursday - October 30, 2014 Bayer operationally strong – strategic focus on Life Science businesses Third quarter of 2014: Sales advance in all subgroups – double-digit percentage growth for CropScience and the Pharmaceuticals Division (Fx & portfolio adj.); Group sales EUR 10,187 million (plus 5.6 percent / Fx & portfolio adj.: plus 7.4 percent); EBIT improves by 12.7 percent to EUR 1,376 million; EBITDA before special items increases by 1.4 percent to EUR 2,011 million; Net income advances by 12.7 percent to EUR 826 million; Core earnings per share grow by 6.3 percent to EUR 1.35; Guidance for full year 2014 raised; Plan to float MaterialScience on the stock market more
Thursday - October 16, 2014 Bayer rated international climate protection leader in the pharmaceutical industry Bayer once again included in CDP Climate Performance Leadership Index more
Tuesday - October 07, 2014 Bayer donates medicines worth USD 3.2 million for Ebola victims Bayer is making drugs with a market value of USD 3.2 million available to the U.S. aid organization Direct Relief free of charge to treat Ebola patients in Sierra Leone and Liberia. more
Thursday - October 02, 2014 Bayer closes acquisition of consumer care business of Merck and Co., Inc., United States, for USD14.2 billion Bayer achieves top global positions in key OTC categories; strategic pharma collaboration between Bayer and Merck & Co., Inc. in the field of sGC modulators takes effect more
Thursday - September 18, 2014 Bayer plans to focus entirely on Life Science businesses Concentration on HealthCare and CropScience / MaterialScience to be floated on the stock market by 2016 at the latest / Planned separation to benefit both Bayer and MaterialScience / Employment levels are expected to remain stable over the next few years more more
Wednesday - July 30, 2014 Second quarter of 2014: Bayer continues positive business development Sales growth in all subgroups; Group sales EUR 10,458 million (plus 0.9 percent; Fx & portfolio adj. plus 6.3 percent); EBIT improves by 14.5 percent to EUR 1,473 million; EBITDA before special items increases by 1.0 percent to EUR 2,217 million – despite negative currency effects of 7 percent; Net income advances by 13.3 percent to EUR 953 million; Core earnings per share level with prior year at EUR 1.53 (minus 0.6 percent); Group outlook for 2014 confirmed more
